Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report[J]. Am J Respir Crit Care Med. 2017;195(5):557. doi:10.1111/resp.13012
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:938–43.23169314
   PubMedGoogle Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
   PubMed Web of Science ®Google Scholar
• GOLD. 2017 Global strategy for the diagnosis, management and prevention of COPD. [cited 210, 2018]. Available from: http://goldcopd.org/download/326/
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191. doi:10.7326/0003-4819-155-3-201108020-0000821810710
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6–14. doi:10.1016/j.rmed.2017.01.00628284323
   PubMed Web of Science ®Google Scholar
• Andreas S, Bothner U, Trampisch M, Haensel M, Buhl R, Alter P. Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther. 2018;52:1–6. doi:10.1016/j.pupt.2018.08.00230077810
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Kerwin EM, Chapman KR, et al. Safety of inhaled glycopyrronium in patients with COPD: A comprehensive analysis of clinical studies and post-marketing data. Int J COPD. 2015;10(1):1599–1612. doi:10.2147/COPD.S81266
   Google Scholar
• Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477–492. doi:10.2147/COPD.S2381622003293
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450. doi:10.1001/jama.300.12.143918812535
   PubMed Web of Science ®Google Scholar
• Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001;12:232–236. doi:10.1159/00005126311244218
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi:10.1136/bmj.327.7420.89512958120
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. doi:10.2307/25334467786990
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
   PubMed Web of Science ®Google Scholar
• Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107:1558–1567. doi:10.1016/j.rmed.2013.05.01623867808
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010;23(3):165–171. doi:10.1016/j.pupt.2010.01.00320080201
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Tosiello R, Price B, Sanjar S, Goodin T. Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2917–2929. doi:10.2147/COPD.S17240830275690
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12(1):156. doi:10.1186/1465-9921-12-12222151296
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14(1):178. doi:10.1186/1471-2466-14-17825404569
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121(4):1058–1069. doi:10.1378/chest.121.4.105811948033
   PubMed Web of Science ®Google Scholar
• Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460–1472. doi:10.1016/j.rmed.2010.06.00420620037
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.00200212
   Web of Science ®Google Scholar
• Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo-and active-controlled trial. Clin Ther. 2007;29(2):261–278. doi:10.1016/j.clinthera.2007.02.00917472819
   PubMed Web of Science ®Google Scholar
• Brook RD, Anderson JA, Calverley PMA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017 heartjnl-2016-310897. doi:10.1136/heartjnl-2016-310897
   Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006;58(5):399–404. doi:10.1136/thx.58.5.399
   Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725. doi:10.1136/thx.2010.13607720685748
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. doi:10.1378/chest.13-157924385182
   PubMed Web of Science ®Google Scholar
• Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68–75. doi:10.1378/chest.10-183021349928
   PubMed Web of Science ®Google Scholar
• Tonnel AB, Perez T, Grosbois JM, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(2):301. doi:10.2147/COPD.S246318686739
   PubMedGoogle Scholar
• Zheng J, Zhong N, Newlands A, et al. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 1753;2015;10:1753–1767. doi:10.2147/COPD.S81053
   Web of Science ®Google Scholar
• Siler TM, Donald AC, O’Dell D, et al. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62. 5/25μg on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971. doi:10.2147/COPD.S10296227274218
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. doi:10.1136/thx.2009.12543520522841
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, LöTvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162. doi:10.1164/rccm.200910-1500OC20463178
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 μ g once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10(1):11. doi:10.1186/1471-2466-10-1120211002
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645. doi:10.2147/COPD.S6171724966672
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged≥ 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011;33(12):1974–1984. doi:10.1016/j.clinthera.2011.11.00922177371
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study. Eur Respir J. 2012;40:1106–1114. doi:10.1183/09031936.00040712
   Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013;107(4):560–569. doi:10.1016/j.rmed.2012.12.01423352226
   PubMed Web of Science ®Google Scholar
• Kerwin E, Donohue JF, Goodin T, et al. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Lee SH, Lwen HANG, et al. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study. Respirology. 2012;17(2):379–389. doi:10.1111/j.1440-1843.2011.02107.x22122202
   PubMed Web of Science ®Google Scholar
• Koch A, Watz H, Maleki-Yazdi MR, et al. Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β 2-agonist formoterol. NPJ Prim Care Respir Med. 2017;27(1):60. doi:10.1038/s41533-017-0059-129061968
   PubMed Web of Science ®Google Scholar
• Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273–279. doi:10.1183/09031936.0004581020693243
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107(4):550–559. doi:10.1016/j.rmed.2012.12.01623332861
   PubMed Web of Science ®Google Scholar
• McGarvey L, Niewoehner D, Magder S, et al. One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015;12(5):484–493. doi:10.3109/15412555.2014.99186425692310
   PubMedGoogle Scholar
• Nelson HS, Gross NJ, Levine B, et al. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo-and active-controlled trial. Clin Ther. 2007;29(10):2167–2178. doi:10.1016/j.clinthera.2007.10.00718042473
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Internal Med. 2005;43(5):317–326. doi:10.7326/0003-4819-144-2-200601170-00021
   Web of Science ®Google Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
   PubMed Web of Science ®Google Scholar
• Rennard SI, Anderson W, ZuWALLACK R, et al. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(5):1087–1092. doi:10.1164/ajrccm.163.5.990305311316640
   PubMed Web of Science ®Google Scholar
• D’Urzo DA, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, Placebo-Controlled AUGMENT COPD Study. Respir Res. 2014;15(1):123. doi:10.1186/s12931-014-0123-025756831
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease. Drugs. 2008;68(14):1975–2000. doi:10.2165/00003495-200868140-0000418778120
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):43–1554. doi:10.1056/NEJMoa080580018596273
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Worth H, Chung KF, Felser JM, et al. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571–579. doi:10.1016/j.rmed.2010.11.02721227674
   PubMed Web of Science ®Google Scholar
• Yao W, Wang C, Zhong N, et al. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26‐week A sia-P acific study. Respirology. 2014;19(2):231–238. doi:10.1111/resp.1221124383720
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAsand LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173. doi:10.1016/j.ejphar.2015.05.02025981302
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016;39:501–508. doi:10.1007/s40264-016-0402-426924197
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. doi:10.1002/ejhf.59227207191
   PubMed Web of Science ®Google Scholar
• Xia N, Wang H, Nie X. Inhaled long-acting β2-agonists do not increase fatal cardiovascular adverse events in COPD: a meta-analysis. PloS One. 2015;10(9):e0137904. doi:10.1371/journal.pone.013790426378450
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD. Pulm Pharmacol Ther. 2017;42:1–6. doi:10.1016/j.pupt.2016.11.00327864038
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321. doi:10.1378/chest.125.6.230915189956
   PubMed Web of Science ®Google Scholar